Home › One Internist's Glance At MannKind's Afrezza
 

Keywords :   


One Internist's Glance At MannKind's Afrezza

2015-01-03 19:28:42| Biotech - Topix.net

I wanted to offer my assessment of the utility of Afrezza as a clinician, after doing a review of some of the available clinical data and evidence. A small meta-analysis of open-label randomized controlled trials from ClinicalTrials.gov indicates that Afrezza was associated with smaller reductions in A1C than control, and higher discontinuation rates.

Tags: glance afrezza

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06XREAL bring Play Store apps to 3D space on XREAL AR glasses
26.06Qwilt reveals live streaming survey results
26.06Rockline Industries Wins WOW Innovation Award
26.06IMS Technologies Expands Calcinate Production Site
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
More »